Annals of Nuclear Medicine

, Volume 33, Issue 12, pp 877–880 | Cite as

From the respective expert viewpoints of the ANM specialty editors

  • Masayuki InubushiEmail author
  • Miho Shidahara
  • Yasuyuki Takahashi
  • Mikako Ogawa
  • Yasushi Kiyono
Open Access
Invited Review Article


Although it may not be well known, the Annals of Nuclear Medicine (ANM) Editorial Committee includes one specialty editor of nuclear medicine physics, one of nuclear medicine technology, one of molecular imaging, and two of radiopharmacology. In addition, a statistics editor and a language editor are also on the committee. Manuscripts submitted to ANM can be peer-reviewed by such specialty editors similar to those submitted to highly ranked journals, which is a great pride and joy to us. To offer our readers a condensed global view on the high-quality research work in the field of nuclear medicine, we have published a mini-review article every year under the joint authorship of the ANM associate editors since 2016. This is our fourth serial review article written by the ANM specialty editors from their respective expert viewpoints.


Dosimetry Harmonic PET Multimodal imaging 18F-labeled boron-derived methionine analogue (18F-B-MET) meta-[211At]Astato-benzyguanidine (211At-MABG) 


To offer our readers a condensed global view of the high-quality research work conducted in the field of nuclear medicine, we have published a mini-review article every year under the joint authorship of the 5–6 associate editors of the Annals of Nuclear Medicine (ANM) since 2016 [1, 2, 3]. This is our fourth serial article written by the final group of 5 authors from about 20 associate editors. Differing from the previous general editor coauthors, the current coauthors are all specialty editors. Although perhaps not well known, the ANM Editorial Committee includes one specialty editor of nuclear medicine physics, one of nuclear medicine technology, one of molecular imaging, and two of radiopharmacology. In addition, a statistics editor and a language editor are also on the committee. Manuscripts submitted to ANM can be peer-reviewed by such specialty editors similar to those submitted to highly ranked journals, which is a great pride and joy to us. In this mini-review article, each ANM specialty editor selects a couple of original articles of their interest from publications in Europe last year, and provide intelligible comments on them from their respective expert viewpoints.

Nuclear medicine physics–dosimetry in radionuclide therapy

Internal dosimetry of radionuclide therapy is still challenging in clinical practice but essential for individualized treatment planning toward maximum tumor response but minimum normal organ toxicity.

Cremonesi et al. performed an elaborate literature survey of peptide receptor radionuclide therapy (PRRT) with both 90Y and 177Lu, and reviewed not only the key relationships among absorbed dose, toxicity and tumor response but also the radiobiological models as usually applied for external beam radiation therapy (EBRT) [4]. For kidney toxicity, besides kidney absorbed dose, there are other factors to be considered including the number of cycles, administered activity for each cycle, total administered activity, and amino acid protection. Furthermore, the possibility of renal functional impairment requires a minimum follow-up of 6 months, and more likely 1 year. In EBRT, fractionated irradiation is a common protocol to maximize the tumor response and minimize healthy organ toxicity. As with EBRT, by selecting the optimal number of cycles and administered doses in total or in each cycle, the incidence of kidney toxicity or severity of kidney impairment can be reduced. To accomplish this, the kidney absorbed dose together with dose-limit (e.g., 23 Gy in kidneys, 177Lu-DOTATATE, 7.4 GBq [5]) have important roles. Of course, the biological effect factor (BEF) based on the radiobiological model of linear quadrant rather than absorbed dose is sensitive in predicting kidney toxicity. However, the kidney absorbed dose in each cycle will be surely an important factor in routine clinical practice, as mentioned by the authors.

To estimate individual dosimetry, one difficulty is how to obtain an individual time-course of administered biodistributions of administered radioligands in each therapeutic cycle, because therapeutic radionuclides (e.g., alpha emitter) are not always suitable for PET or SPECT imaging. Use of a surrogate nuclide assuming the same biodistribution/biological decay but only different physical decay is one possible solution. Kratochwil et al. performed serial whole-body PET imaging with 68 Ga-PSMA-617 as the surrogate radioligand and extrapolated to 213Bi-PSMA-617, and then finally estimated the equivalent dose by MIRD and a two spherical model for tumor lesions and salivary glands while considering daughter nuclides (209Tl, 213Po and 209Pb) [6]. Despite their practical approaches, they noted the methodological uncertainty of approx. 20% for the average values of their patients, without referring to individual organ masses. For MIRD, different body weight (and organ masses) as compared with the male adult phantom (74 kg) leads to over- or under-estimation of the kidney-absorbed dose, which also easily applies to many Japanese patients. So far, internal dosimetry of diagnostic-purpose radiopharmaceuticals has been performed for group studies; however, in the case of radionuclide therapy, it would be preferable to obtain dose-estimates individually whenever possible with high accuracy. For more accurate individual internal dosimetry of radionuclide therapy, easy to be introduced in clinical practice but quantitative whole-body imaging techniques (possibly with shorter scan time) would be necessary and the use of individual organ masses/S-values for MIRD may be preferred.

Nuclear medicine technology–harmonic PET

In PET/CT studies of 18F-FDG, scientific societies such as the EANM and SNMMI are closely collaborating to promote standardization of practices, to reduce the variability of quantification in multi-center clinical trials. However, image reconstruction techniques such as time-of-flight (TOF), point spread function (PSF), normalization, randoms, scatter and attenuation corrections in PET systems, and the characteristics of PET scanners such as the type of scintillator, show considerable variation. As a result of these efforts, the use of harmonization is spreading [7]. Harmonization stabilizes SUVs and improves lesion detection while maintaining the performance of many PET systems. Harmonic reconstruction mode employs mean contrast recovery (MCR) and contrast recovery variability. In addition, Gibbs overshoots, partial volume effects, and the reproducibility of signals below 17 mm in diameter are issues that must be addressed in PET images.

This report clearly describes how to improve the quantification that can be achieved with current PET systems [7]. In addition, in examining 18 scanners from three major vendors, most of today's main devices are covered. Phantom study complied with the EANM/EARL guidelines for Image Quality QC. Emission scan times were adjusted by list mode from 5 min per bed position, and 15 reconstruction conditions were consolidated into approximately five. Two or three iterations with 21 or 24 subsets were used for image reconstruction, based on maximum-likelihood and expectation–maximization. The following four points were of particular interest:
  1. 1.

    Before and after the conditions suggested for harmonization, the curvature of SUVmax improved from 0.076–0.290 to 0.212–0.267, and absolute errors of SUVmax improved from 0.157–0.566 to 0.170–0.232.

  2. 2.

    In visual analysis for harmonization, quantitative cutoff criteria were determined based on the bandwidth and characteristics of harmonizing reconstruction modes.

  3. 3.

    SUVpeaks for spheres less than 17 mm in diameter have a low recovery rate, and MCR is significantly (20–40%) lower than SUVmax. By reducing the VOI size, SUVpeak may be become an effective alternative to SUVmax.

  4. 4.

    Using the workstation's post-smoothing function, higher recoveries could reduce noise and Gibbs artefacts to acceptable levels for harmonization.


Previous harmonization was not used to the complexity of including TOF and PSF. In the future, harmonization is also expected to PET systems featuring the current silicon photo multiplier (SiPM) and depth of interaction (DOI) detector.

Molecular imaging–multimodal imaging

The combination of nuclear and optical imaging should be efficient; however, most studies are limited to animal experiments or small-scale clinical trials. KleinJan GH, et al. have tested indocyanine green (ICG)-99mTc dual-labeled nanocolloid for sentinel lymph node (SN) detection in relatively large clinical studies [8]. ICG is a near-infrared fluorophore that is used for lymphatic imaging in the clinic. In this study, they used not free ICG but ICG-colloid that is also labeled with 99mTc to avoid leakage of the tracer into the surgical field. They compared intraoperative radioguidance, fluorescence guidance with hybrid tracer and optical guidance with blue dye. The find rates of SNs with blue dye were significantly poorer than those of the hybrid tracer. The advantages of fluorescence imaging are ease of use and high resolution during surgery. Fluorescence guidance was superior to radioguidance in anatomically complex areas and for identification of lymph nodes next to the injection site. However, since the permeability of the fluorescence is not sufficient, it was difficult to detect the signal from deep tissue. In this article, it is revealed that SNs located at a depth of 0.5–1 cm could not be detected by fluorescence guidance. Fluorescence guidance is effective, but radioguidance remains essential for in vivo SN localization. This article showed the effectiveness of multimodal imaging in the clinic to take advantage of each imaging modality and compensate for their respective shortcomings.

Radiopharmacology—novel radiopharmaceuticals for diagnosis and therapy

11C-Methionie is a useful PET tracer for detecting and grading gliomas. However, due to its short half-life (20.38 min), extensive application of 11C-methionine is limited. Yang et al. have developed 18F-labeled boron-derived methionine analogue, 18F-B-MET [9]. This tracer successfully distributed in mice glioma, and orthotropic tumors were clearly visualized with low background signal in normal brain. The notable points of this article are not only the efficacy of this tracer as a substitute for 11C-methionine, but also the simple radiolabeling method. In this article, 18F labeling was performed by 18F-19F isotope exchange reaction, using 19F-B-MET as a precursor. The reaction was performed by just mixing the chemicals including 18F-fluoride in an aqueous solution, with a high radiochemical yield and short synthesis time accomplished. The biggest concern was low specific activity. Separation from the precursor is impossible since the precursor and product are chemically identical. But, in this article, specific activity was more than 37 GBq/μmol, which is acceptable for most imaging probes. The reaction was performed with only 10 nmol precursor due to the high reactivity of this method, and thus relatively high specific activity was accomplished. As the authors mention in this article, the isotope exchange 18F labeling should not only simplify the methodology, but also provides high yields to lower the bar for various clinical applications.

The development of radiopharmaceuticals for internal radiation therapy (or targeted radionuclide therapy: TNT) has been increasing. From the point of view of therapeutic radionuclides, α-emitters are attractive radionuclides exerting strong therapeutic effects with minimal side effects. 211At is one such suitable α-emitter because 211At is a halogen and has similar characteristics to those of 131I. Oshima, et al. investigated the therapeutic effect of meta-[211At]astato-benzyguanidine (211At-MABG) which was an α-emitting type of meta-iodo-benzyguanidine (MIBG) in a pheochromocytoma (PC-12 cells) model both in vitro and in vivo [10]. In this study, they demonstrated that 211At-MABG reduced the PC-12 cell survival ratio in a dose-dependent manner, with this cell death induced by DNA double-strand breaks in an in vitro study. In an in vivo study, treatment with 211At-MABG reduced the tumor volumes in PC12 tumor-bearing mice in a dose-dependent manner. In addition, reductions in body weight and in the number of myeloid cells in the bone marrow were not severe in mice treated with 211At-MABG. This article showed the effectiveness of 211At-MABG treatment of malignant pheochromocytoma.

From the point of view of therapeutic targets, angiogenesis is an attractive target because when increased it is a marker of aggressiveness in many cancers. CD105 is an endothelial cell marker that has been suggested to be a suitable biomarker for angiogenesis, and it has a very limited biodistribution in normal tissue. Ehlerding, et al. developed 177Lu-DTPA-TRC105 as CD105 targeted radiopharmaceuticals as a widely applicable target for targeted radioimmunotherapy [11]. Using breast cancer model mice, they demonstrated that 177Lu-DTPA-TRC105 was steadily accumulated in 4T1 tumors between 1 and 7 days after injection. Furthermore, significant inhibition of tumor growth was observed in a group treated with 11 MBq of 177Lu-DTPA-TRC105, with a corresponding significant increase in survival. The body weights of the mice did not significantly decrease, and the blood counts indicated minimal differences in toxicity markers. From these results, 177Lu-DTPA-TRC105 would appear to be a promising radiopharmaceutical for targeted angiogenesis.


The ANM specialty editors of nuclear medicine physics, nuclear medicine technology, molecular imaging, and radiopharmacology provided intelligible comments on research in their respective specialties that has attracted their interest. This mini-review article highlighted mainly basic research articles that have been published in the European Journal of Nuclear Medicine and Molecular Imaging (EJNMMI) in 2018. This world-leading journal also published many outstanding clinical research articles; we suppose that targeted radiotherapy using prostate-specific membrane antigen (PSMA) radioligands in prostate cancer patients [12, 13, 14, 15, 16, 17] must be a particular focus of attention for most ANM readers in Japan, who are waiting impatiently for its approval by the Japanese government. This topic will be fully discussed in our next serial review article in the near future.



This work was not supported financially.

Compliance with ethical standards

Conflicts of interest

The authors declare that they have no conflicts of interest.


  1. 1.
    Inubushi M, Higashi T, Kuji I, Sakamoto S, Tashiro M, Momose M. Introduction of nuclear medicine research in Japan. Eur J Nucl Med Mol Imaging. 2016;43:2449–522.CrossRefGoogle Scholar
  2. 2.
    Inubushi M, Kaneta T, Ishimori T, Imabayashi E, Okizaki A, Oku N. Topics of nuclear medicine research in Europe. Ann Nucl Med. 2017;31:571–4.CrossRefGoogle Scholar
  3. 3.
    Inubushi M, Tatsumi M, Yamamoto Y, Kato K, Tsujikawa T, Nishii R. European research trends in nuclear medicine. Ann Nucl Med. 2018;32:579–82.CrossRefGoogle Scholar
  4. 4.
    Cremonesi M, Ferrari ME, Bodei L, Chiesa C, Sarnelli A, Garibaldi C, et al. Correlation of dose with toxicity and tumour response to 90Y- and 177Lu-PRRT provides the basis for optimization through individualized treatment planning. Eur J Nucl Med Mol Imaging. 2018;45:2426–41.CrossRefGoogle Scholar
  5. 5.
    Sandstrom M, Garske-Roman U, Granberg D, Johansson S, Widstrom C, Eriksson B, et al. Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment. J Nucl Med. 2013;54:33–41.CrossRefGoogle Scholar
  6. 6.
    Kratochwil C, Schmidt K, Afshar-Oromieh A, Bruchertseifer F, Rathke H, Morgenstern A, et al. Targeted alpha therapy of mCRPC: dosimetry estimate of 213Bismuth-PSMA-617. Eur J Nucl Med Mol Imaging. 2018;45:31–7.CrossRefGoogle Scholar
  7. 7.
    Kaalep A, Sera T, Rijnsdorp S, Yaqub M, Talsma A, Lodge MA, et al. Feasibility of state of the art PET/CT systems performance harmonisation. Eur J Nucl Med Mol Imaging. 2018;45:1344–61.CrossRefGoogle Scholar
  8. 8.
    Klein Jan GH, van Werkhoven E, van den Berg NS, Karakullukcu MB, Zijlmans HJMAA, van der Hage JA, van de Wiel BA, Buckle T, Klop WMC, Horenblas S, Olmos VRA, van der Poel HG, van Leeuwen FWB. The best of both worlds: a hybrid approach for optimal pre- and intraoperative identification of sentinel lymph nodes. Eur J Nucl Med Mol Imaging. 2018;45:1915–25.CrossRefGoogle Scholar
  9. 9.
    Yang X, Liu Z, Zhang H, Li Z, Munasinghe JP, Niu G, Teng G, Chen X. Preclinical evaluation of an 18F-trifluoroborate methionine derivative for glioma imaging. Eur J Nucl Med Mol Imaging. 2018;45:585–92.CrossRefGoogle Scholar
  10. 10.
    Ohshima Y, Sudo H, Watanabe S, Nagatsu K, Tsuji AB, Sakashita T, et al. Antitumor effects of radionuclide treatment using α-emitting meta-211At-astato-benzylguanidine in a PC12 pheochromocytoma model. Eur J Nucl Med Mol Imaging. 2018;45:999–1010.CrossRefGoogle Scholar
  11. 11.
    Ehlerding EB, Lacognata S, Jiang D, Ferreira CA, Goel S, Hernandez R, et al. Targeting angiogenesis for radioimmunotherapy with a 177Lu-labeled antibody. Eur J Nucl Med Mol Imaging. 2018;45:123–31.CrossRefGoogle Scholar
  12. 12.
    Rahbar K, Boegemann M, Yordanova A, Eveslage M, Schäfers M, Essler M, et al. PSMA targeted radioligand therapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival. Eur J Nucl Med Mol Imaging. 2018;45:12–9.CrossRefGoogle Scholar
  13. 13.
    Rahbar K, Bögeman M, Yordanova A, Eveslage M, Schäfers M, Essler M, et al. Delayed response after repeated 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45:243–6.CrossRefGoogle Scholar
  14. 14.
    Rahbar K, Ahmadzadehfar H, Boegemann M. 177Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial? Eur J Nucl Med Mol Imaging. 2018;45:513–4.CrossRefGoogle Scholar
  15. 15.
    von Eyben FE, Roviello G, Kiljunen T, Uprimny C, Virgolini I, Kairemo K, et al. Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review. Eur J Nucl Med Mol Imaging. 2018;45:496–508.CrossRefGoogle Scholar
  16. 16.
    Virgolini I, Decristoforo C, Haug A, Fanti S, Uprimny C. Current status of theranostics in prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45:471–95.CrossRefGoogle Scholar
  17. 17.
    Kelly J, Amor-Coarasa A, Ponnala S, Nikolopoulou A, Williams C Jr, Schlyer D, et al. Trifunctional PSMA-targeting constructs for prostate cancer with unprecedented localization to LNCaP tumors. Eur J Nucl Med Mol Imaging. 2018;45:1841–51.CrossRefGoogle Scholar

Copyright information

© The Author(s) 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  • Masayuki Inubushi
    • 1
    Email author
  • Miho Shidahara
    • 2
  • Yasuyuki Takahashi
    • 3
  • Mikako Ogawa
    • 4
  • Yasushi Kiyono
    • 5
  1. 1.Division of Nuclear Medicine, Department of RadiologyKawasaki Medical SchoolKurashikiJapan
  2. 2.Department of Quantum Science and Energy Engineering, Graduate School of EngineeringTohoku UniversitySendaiJapan
  3. 3.Department of Radiation Science, Graduate School of Health SciencesHirosaki UniversityHirosakiJapan
  4. 4.Laboratory for Bioanalysis and Molecular Imaging, Graduate School of Pharmaceutical SciencesHokkaido UniversitySapporoJapan
  5. 5.Biomedical Imaging Research CenterUniversity of FukuiFukuiJapan

Personalised recommendations